Familial combined hyperlipidemia is a hereditary disorder characterized by elevated plasma lipid levels, including cholesterol and triglycerides. This condition is caused by abnormal lipid metabolism, which can lead to atherosclerosis, cardiovascular disease, and other complications. The disease is polygenetic in nature and is associated with abnormalities in several genes that regulate lipoprotein transport and metabolism. It is important to note that combined hyperlipidemia can occur alongside other diseases, such as diabetes, obesity, and hypertension, making diagnosis and treatment complex and multifaceted.
History of the disease and interesting historical facts
Familial combined hyperlipidemia was first described in medicine in the mid-20th century, when budding geneticists began to study the relationship between heredity and lipid metabolism pathology. In the 1970s, studies by scientists such as Brown and Goldstein demonstrated a link between cholesterol levels and heart disease, which contributed to a deeper understanding of this pathology. Interestingly, combined hyperlipidemia is more common in certain ethnic groups, which also opens up new horizons for the study of genetic predispositions and metabolic features in different populations.
Epidemiology
According to various sources, the prevalence of familial combined hyperlipidemia varies from 1% to 5% in the population. Studies show that this disease is most common in people of European descent. Scientists also note that the prevalence of hyperlipidemia increases significantly in groups with a high genetic predisposition, which should be perceived as a signal for a more in-depth study of this problem in the context of lifestyle changes.
Genetic predisposition to this disease
Familial combined hyperlipidemia is often associated with mutations in genes such as LDLR, APOB, and PCSK9, which play a key role in lipoprotein metabolism. Mutations in these genes lead to disruption of the normal removal of LDL cholesterol from the body, which in turn contributes to elevated plasma levels. Research confirms the role of polygenic variations in these genes and others, highlighting the multifactorial nature of this disease.
Risk factors for the development of this disease
Risk factors that contribute to the development of familial combined hyperlipidemia can be divided into genetic and environmental. Genetic factors include:
- Having close relatives with the disease;
- The presence of mutations in the specified genes;
- Changes in the regulation of lipid metabolism.
Environmental factors include:
- Improper diet, rich in fats;
- Lack of physical activity;
- Smoking and drinking alcohol;
- Stress and lack of sleep.
Diagnosis of this disease
Diagnosis of familial combined hyperlipidemia involves several key components. Most often, there are no major symptoms of the disease, but in some cases, chronic fatigue, chest pain, and discomfort may occur. Laboratory tests are aimed at assessing lipid levels, including total cholesterol, triglycerides, HDL, and LDL. Radiological tests, such as abdominal ultrasound, can be used to assess the organs involved in lipid metabolism. An important step in diagnosis is the differential diagnosis to exclude other diseases, such as diabetes or thyroid disease.
Treatment
Treatment of familial combined hyperlipidemia should be comprehensive. General treatment includes lifestyle changes such as diet, physical activity, and avoiding harmful habits. Pharmacological treatment is often necessary and may include statins, fibrates, and PCSK9 inhibitors. In some cases, when drug therapy is ineffective, surgical intervention, such as laser treatment of atherosclerotic plaques, may be considered.
List of medications used to treat this disease
- Atorvastatin;
- Rosuvastatin;
- Simvastatin;
- Fenofibrate;
- Ezetimibe;
- PCSK9 inhibitors (Alirocumab, Evolocumab).
Disease monitoring
Monitoring of familial combined hyperlipidemia involves regular checks of lipid levels and assessment of the effectiveness of therapy. Control steps include:
- Measuring lipid levels every 3-6 months;
- Assessment of the state of the cardiovascular system;
- Adjustment of treatment if necessary.
The prognosis with the right approach to treatment is usually positive, but ignoring the disease can lead to serious complications such as myocardial infarction or stroke.
Age-related features of the disease
Familial combined hyperlipidemia can manifest at any age, but is most often diagnosed in adulthood. In children and adolescents, the disease may progress atypically, which complicates diagnosis. Older people often have more pronounced symptoms and age-related comorbidities, which requires a more careful approach to treatment and monitoring.
Questions and Answers
- What are the main signs and symptoms of familial combined hyperlipidemia? There may be no major symptoms, but fatigue, chest pain or discomfort may sometimes occur.
- How is this disease diagnosed? Diagnosis is based on laboratory tests of lipid levels and may also include radiological examinations and differential diagnosis.
- What treatment is effective for familial combined hyperlipidemia? Treatment involves lifestyle changes and drug therapy, including the use of statins and other drugs.
- What is the prognosis for patients with this disease? The prognosis, if treatment recommendations are followed, is generally favorable.
- What is the significance of genetic predisposition? Genetic predisposition plays a key role in the development of the disease, since many lipid metabolism pathologies are hereditary.
Advice from Dr. Oleg Korzhikov
As a specialist, I recommend considering the following aspects for successful control of familial combined hyperlipidemia:
- Regular lipid screening and health monitoring;
- Eating a diet low in saturated fat and carbohydrates;
- Physical activity that should become part of your daily routine;
- Avoiding stress and improving sleep quality, which is also important for overall health;
- Consult your doctor about medication and possible side effects.
Maintaining a healthy lifestyle and regular medical examinations can significantly reduce risks and improve quality of life.
